Total Cost of Care

Kidney-focused VBC models are facing renewed scrutiny as recent analysis argues that the major investment wave in kidney care has not materially reduced hospital costs because interventions remain too narrowly targeted—often engaging patients too late in CKD/ESRD progression rather than managing upstream comorbidities, transitions, and avoidable acute episodes across total cost of care. For ACOs, MA plans, nephrology groups, and CMMI model participants, the implication is that kidney care savings will likely depend less on standalone disease-management overlays and more on earlier risk stratification, primary-care integration, and shared accountability for inpatient utilization (MedCity News). A parallel Medicaid cost-control signal is emerging around earlier cancer screening, where moving diagnosis upstream could reduce late-stage treatment spend and strengthen population-health performance for Medicaid managed care plans and safety-net systems (AJMC).